

# 2023 FY Results

March 2024



# China's Leading Innovative Pharmaceutical Enterprise



## R&D Capabilities

- **8** R&D platforms
- **5** R&D centres located in China & the U.S.
- ~ **2,000** R&D staff
- ~ **300** R&D projects (~**130** innovative projects)



## Commercialization Capabilities

- **10,000+** professional sales personnel
- Covered **35,000+** medical institutions across the country, of which **2,900+** Class 3 hospitals (more than 90%), **7,000+** Class 2 hospitals (more than 70%), **26,000+** other terminals and **350,000+** drug stores
- Products exported to **114** countries/regions in 6 continents, including the U.S. and Europe; marketing centers established in the U.S., Germany and Brazil



## Manufacturing Capabilities

- **10+** pharmaceutical production bases
- Nano formulation: **27** production lines built with production capacity of **20M** doses/year; **2** production lines under construction with production capacity of **2M** doses/year
- Biologics: fermentation capacity of **40,000L**
- Chemical drugs: production capacity of OSD~**30B** tablets/year, production capacity of injection ~**3B** doses/year
- mRNA vaccines: GMP-compliant production plant has been built
- siRNA: 2 pilot scale production lines has been built; commercial scale production line is under construction





# 2023 FY Highlights

## R&D

### 5 new drug approvals:

- Mingfule(AIS)
- Covid-19 mRNA vaccine (EUA)
- Narlumobart for injection
- Irinotecan liposome injection
- COVID-19 bivalent mRNA vaccine (EUA)

### 7 applications for marketing approval :

#### China

- Amphotericin B liposome
- Prugliptin tablets (DPP-4)
- Omalizumab for injection
- Meloxicam nanocrystal injection
- Enlonstobart for injection

#### North America

- Amphotericin B liposome for injection
- Irinotecan liposome injection

### 46 IND approvals :

#### China

17 for the first indication  
24 for additional indications

#### North America

5 for the first indication



## Business

- Revenue increased by **1.7%** to **RMB31.45B**
- Underlying profit attributable to shareholders\* (see page 6) increased by **2.8%** to **RMB6.28B**

## BD

- Nectin-4ADC: licensed-out the rights in the US, EU, UK, Canada, Australia, Iceland, Liechtenstein, Norway and Switzerland to Corbus, with **US\$7.5M** upfront payment, potentially **US\$685M** milestone payment and royalty.
- Obtained the exclusive promotion rights of Glumetinib (c-MET inhibitor) from Haihe Biopharma. The product has been approved for marketing in March 2023
- Signed a strategic partnership agreement with Pfizer to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China



01

**Financial  
Highlights**

02

**Business  
Review**

03

**R&D  
Capabilities**

04

**Pipeline**

05

**BD & ESG**





Part 01

Financial Highlights


# Financial Highlights

Unit: RMB MM


	2023	2022	Change
Revenue	31,450	30,937	+1.7%
Gross profit	22,177	22,256	-0.4%
Gross profit margin	70.5%	71.9%	-1.4%
R&D expenses	4,831	3,987	+21.2%
Underlying profit attributable to shareholders*	6,275	6,106	+2.8%
Profit attributable to shareholders	5,873	6,091	-3.6%
Basic earnings per share (RMB cents)			
• Based on underlying profit attributable to shareholders	52.86	51.23	+3.2%
• Based on profit attributable to shareholders	49.47	51.11	-3.2%

\*Note:


Underlying profit attributable to shareholders, a non-HKFRS measure, represents profit excluding fair-value losses on financial assets recognised in profit or loss at fair value, share-based employee remuneration expenses and gains on deemed disposal of partial interest in an associate and a joint venture.



**Underlying profit attributable to shareholders**



**Profit attributable to shareholders**



# Revenue

## Revenue by product category

Unit: RMB MM

	2023	2022	Change
<b>Finished drugs</b>	25,637	24,520	+4.6%
<b>Bulk vitamin C</b>	1,929	2,529	-23.7%
<b>Bulk antibiotics</b>	1,712	1,503	+13.9%
<b>Functional Food and Others</b>	2,172	2,385	-8.9%



## Finished drug revenue

Unit: RMB MM

	2023	2022	Change
<b>Nervous system</b>	9,089	8,108	+12.1%
<b>Oncology</b>	6,139	7,340	-16.4%
<b>Anti-infective</b>	4,236	3,540	+19.7%
<b>Cardiovascular</b>	2,440	2,889	-15.5%
<b>Respiratory system</b>	1,560	696	+124.0%
<b>Digestion &amp; metabolism</b>	889	755	+17.8%
<b>Others</b>	1,249	1,006	+24.1%
<b>License fee income</b>	35	186	-81.3%



# Operating Profit

Unit: RMB MM

	<b>2023</b>	<b>2022</b>	<b>Change</b>	<b>2023 OPM</b>	<b>2022 OPM</b>	<b>Change</b>
<b>Finished drug</b>	6,700	6,068	+10.4%	26.1%	24.7%	+1.4%
<b>Bulk vitamin C</b>	5	443	-98.9%	0.3%	17.5%	-17.3%
<b>Bulk antibiotics</b>	154	114	+35.2%	9%	7.6%	+1.4%
<b>Functional Food and Others</b>	561	647	-13.3%	25.9%	27.1%	-1.2%

Note: certain percentage changes of financial figures contained in this material are calculated based on the corresponding financial figures in RMB for two periods/years, rounded to the nearest thousand. Therefore, the percentage changes listed in certain tables may differ from those calculated based on the financial figures in RMB for two periods/years, which are presented in million.






Part 02

Business Review

# Finished Drug Overview by Therapeutic Areas



<b>Nervous system</b>	<ul style="list-style-type: none"> <li>Major products include NBP (butylphthalide soft capsules, butylphthalide and sodium chloride injection), Shuanling (pentoxifylline extended-release tablets, pentoxifylline injection), Oulaining (oxiracetam capsules, oxiracetam for injection), Enxi (pramipexole dihydrochloride tablets), Enliwei (lacosamide injection, lacosamide tablets), and Oushuan (paliperidone extended-release tablets)</li> </ul>
<b>Oncology</b>	<ul style="list-style-type: none"> <li>Major products include Duomeisu (doxorubicin hydrochloride liposome injection), Jinyouli (PEG-rhG-CSF injection), Keaili (paclitaxel for injection (albuminbound)) Duoenda (mitoxantrone hydrochloride liposome injection), Duoenyi (irinotecan hydrochloride liposome injection), Jinlitai (Narlumobart injection), Copiktra (duvelisib capsules) and Geruite (lenvatinib mesilate capsules)</li> </ul>
<b>Anti-infective</b>	<ul style="list-style-type: none"> <li>Major products include Anfulike (amphotericin B cholesteryl sulfate complex for injection), Shuluoke (meropenem for injection), Nuomoling (amoxicillin capsules), Xianqu (Ceftriaxone Sodium for Injection), Xianwu (Cefazolin Sodium for Injection), Zhongnuo Lixin (Cefuroxime Sodium For Injection), and Weihong (azithromycin tablets/capsules/enteric-coated tablets, azithromycin for injection)</li> </ul>
<b>Cardio-vascular</b>	<ul style="list-style-type: none"> <li>Major products include Xuanning (levamlodipine maleate tablets and dispersible tablets), Mingfule (recombinant human TNK tissue-type plasminogen activator for injection), Encun (clopidogrel bisulfate tablets), Daxinning (dronedarone hydrochloride tablets), Abicang (Aspirin enteric-coated tablets), Yishuning (nifedipine controlled-release tablets), and Meiluolin (Ticagrelor tablets)</li> </ul>
<b>Respiratory system</b>	<ul style="list-style-type: none"> <li>Major products include Yiluoda (nintedanib capsules), Qixin (oseltamivir phosphate capsules), Qixiao (arbidol hydrochloride tablets), Nuoyian (montelukast sodium tablets/chewable tablets), Zhongnuo Like (ambroxol hydrochloride oral solution) and Zhongnuoping (ambroxol hydrochloride extended-release tablets)</li> </ul>
<b>Digestion &amp; metabolism</b>	<ul style="list-style-type: none"> <li>Major products include Debixin (omeprazole enteric capsules/tablets/injections), Linmeixin (glimepiride dispersible tablets), Shuanglexin (metformin hydrochloride tablets/extended-release tablets), Xinweiping (acarbose tablets), and Obeituo (Esomeprazole magnesium enteric-coated capsules)</li> </ul>
<b>Others</b>	<ul style="list-style-type: none"> <li>Major products include Oubida (Apgumilast tablets), Gujie (Tofacitib citrate sustained release tablets), Gubang (alendronate sodium tablets/enteric tablets), Xianpai (omeprazole sodium for injection), and Qimaite (tramadol hydrochloride tablets)</li> </ul>



# Key Products Overview

## NBP

### Butylphthalide soft capsules and injections

- 1st Class 1 new drug of cardio-cerebrovascular field in China
- Price cut after negotiation improves affordability and accessibility, benefiting more patients
- Significant growth in OTC and E- channels
- New indication - vascular dementia (VaD) under clinical trials

## Mingfule

### Recombinant human TNK tissue-type plasminogen activator for injection

- For thrombolytic therapy in patients with acute ischemic stroke
- For thrombolysis in patients with acute myocardial infarction within 6h
- Preferred thrombolytic drug recommended by authoritative guidelines such as “*Chinese Expert Consensus on Pre-hospital Thrombolysis*”, “*STEMI Rational Drug Use Guide*”, “*2023 SIGN Clinical Management Guide*”, and “*Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke*”

## Ouyuexin

### Desvenlafaxine succinate extended-release tablets

- The third-generation antidepressant, the only two-channel drug that does not require dose-titration, easy to use with good safety
- "The second batch of encourage imitation drug catalogue" variety, China's first imitation, exclusive listing
- Approved in 2023, was included in the NRDL the same year, benefiting more depressed patients

## Xuanning

### Levamlodipine maleate tablets and dispersible tablets

- The first Chinese innovative antihypertensive drug fully approved by the U.S. FDA
- Has served 50 million hypertensive patients in China
- Recommended by authoritative guidelines such as “*China Hypertension Prevention Guide*” and “*Guidelines for Rational Drug Use of Hypertension*”

## Anfulike

### Amphotericin B cholesteryl sulfate complex for injection

- Exclusive product, obtained marketing approval in March 2021; was included in the NRDL in December 2021
- Have covered approx. 1,600 hospitals
- Form of discoid compound, has a unique drug uptake and release mechanism, significantly decrease nephrotoxicity and increase dosage





# Key Products Overview

## Jinyouli

### PEG-rhG-CSF

- 1st long-acting white blood cell booster drug in China
- Expanding coverage in major municipal hospitals and county-level markets
- Was included in the centralised procurement of the Guangdong Alliance, which consists of 11 provinces, and improving access to the drug would accelerate wider clinical use

## Duomeisu

### Doxorubicin Hydrochloride liposome injection

- Largest market share in China
- The first player who passed consistency evaluation

## Duoenda

### Mitoxantrone hydrochloride liposome injection

- Obtained marketing approval in January 2022, exclusive new preparation worldwide authorized by multinational patents, more potent and safer than mitoxantrone
- Was included in the NRDL through national talks in Dec. 2023, benefiting more patients
- Various clinical trails in solid tumors undergoing, blockbuster potential

## Duoenyi

### Irinotecan hydrochloride liposome injection

- First generic drug in domestic market
- In combination with 5-fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic pancreatic cancer after disease progression following gemcitabine-based therapy
- Recommended by domestic and foreign authoritative guidelines (NCCN/CSCO/CACA)

## Jinlitai

### Narlumosbart for injection

- The first IgG4 subtype fully human monoclonal antibody against RANKL obtaining marketing approval in the world
- Compared with denosumab, the Product has significant enhancement in uniformity and quality controllability, with favorable efficacy and safety profile
- New indications of tumor bone metastasis and osteoporosis are under development





# Bulk Product Business, Functional Food and Others

## Bulk vitamin C

- Major products: vitamin C, vitamin C - sodium, vitamin C - calcium and granular vitamin C
- Sales of vitamin C products decreased by 23.7%, mainly due to the weakening price of vitamin C products

## Bulk antibiotics

- Major products: 7-ACA (intermediate), cefazolin sodium, penicillin potassium, penicillin sodium, azithromycin, and ertapenem sodium
- Sales of antibiotic products increased by 13.9%, driven by the growth in sales volume

## Functional food and others

- During the period, there was a certain decline in the price of caffeine products, while the sales volume maintained a stable growth
- The overall market share of caffeine products has exceeded 60%



Part 03

R & D Capability

# R&D Overview



## R&D Centre

- 5 R&D centres located in China & the U.S.
- R&D expenses in FY 2023: RMB 4.83 B



## Technology Platform

- 8 national science & technology qualifications
- 2 state key labs
- 8 R&D technology platforms



## Project under Development & IPs

- Approx. 300 projects under development (approx. 130 innovative drug projects)
- 1806 IPs applications
- 906 IPs authorised




## Science Projects & Government Support

- 87 national projects
- RMB890M government grant support
- 8 national prizes


# Innovative R&D Platforms

## Nano-formulation



- Mitoxantrone liposome
- Albumin-bound docetaxel
- Paclitaxel cationic liposome
- Cisplatin micelle

## mRNA vaccine




- Covid-19 mRNA vaccine, RSV mRNA vaccine and various preventive and therapeutic vaccines

## siRNA



- PCSK9 siRNA and other chronic disease drugs

## ADC



- CLDN18.2 ADC
- Nectin-4 ADC
- EGFR-ADC

## BsAb




- JMT601 (CD47/CD20)
- JMT106 (GPC3/IFN)
- JMT108 (\*\*/IL15)

## mAb




- JMT101 (EGFR)
- JMT103 (RANKL)
- ALMB0168 (CX43 agonist)
- ALMB0166 (CX43 antagonist)

## Small molecule



- Prugliptin (DPP-4)
- Amuxetine
- SYHX1901 (Syk-Jak)
- SYHA1813 (VEGFR/CSF1R)

## Long-acting injection



- Octreotide Long-acting injection
- Paliperidone injection
- Leuprorelin microsphere injection

Note: only shows the representative products on each platform



# Nano-formulation Platform



## Nano-formulation development and manufacturing platform



### Novel drug carrier design

- Invented Albumin nanoemulsion
- Developed new cationic materials and new delivery system

### Novel drug delivery technology


- Invented ammonium salt gradient method of sulfobutylether- $\beta$ -cyclodextrin and 5-sulfosalicylate
- Cholesterol PEGylation modification method and post single layer PEGylation

### Novel preparation method

- Invented single-phase solution lyophilization technology, O/W type Emulsification technology, crossflow mixing technology, continuous flow reaction technology, etc.
- Invented bottom up nanocrystal preparation technology, enabling continuous production

### Novel Industrialized production technology

- Invented continuous flow technology, employing linear amplifier, overcome barriers to industrialized production
- Illustrated that all nano drugs are able to be prepared by permutation and combination of four key processes



## Nano-formulation assessment system



### Particle characterisation method

- Developed nano-formulation assessment technology for liposome, albumin nanoparticles, emulsion, micelles, etc.

### PK determination method

- Established multiple PK determination methods for nano drugs including liposome, albumin nanoparticle, micelles etc.

### Mature animal screening models

- Established multiple animal disease model for efficacy assessment
- Established animal models for evaluating ABC phenomenon, CARPA response and HFS, enabling quick screening

### Particle characterisation technique guided in vivo PK, PD, TOX evaluation

- Illustrated influence of drug release rate of liposome, mode of administration and animal model on ABC phenomenon
- Detailed study of CARPA and HFS laid the foundations for rational design of nanoparticles

The largest R&D and industrialization base for Nano- Formulation

# mRNA Vaccine platform

## 1 Advantages of antigen design

- Mutation prediction platform
- The combination of bioinformatics and structural biology to obtain effective epitopes
- Superior immunogenicity from site-specific mutation of antigen

## 2 mRNA vaccine design

- Base modification, UTR screening, codon optimization and structural elements inclusion
- Structural energy optimization to enhance antigen expression

## 3 Manufacturing capabilities

- Manufacturing capabilities of CSPC
- Top tier LNP R&D platform
- Manufacturing capacity reaches to 1.5 billion doses per year

## 4 Excellent safety profile

- No observed SAE in clinical trials
- Excipients proven to be low toxicity by launched products
- Base modification mitigates innate immunogenicity
- Formulation ensures long-term stability

## 5 Streamlined CMC Strategy

- One-step API manufacturing process
- API purification process: up to 99% purity
- Highly scalable LNP manufacturing process
- Short turnaround time: ~2 days

## 6 Highly expandable platform

- Each individual component can be continuously upgraded
- Expansion from linear mRNA to circRNA; from liver-target delivery to extrahepatic delivery
- From preventive to therapeutic application; from vaccine to CGT



# siRNA Platform

## 1 HTS screening platform

- Rational sequence design based on bioinformatics and experienced scientists
- Comprehensive in vitro and in vivo PK/PD characterization

## 2 CMC platform

- Build strong oligonucleotides CMC platform based on QbD strategy
- Develop liquid synthesis technology

## 3 Manufacturing capabilities

- Manufacturing capabilities of CSPC
- Two GMP-compliant production lines have been built

## 4 Excellent safety profile

- Build off-target risk assessment platform
- Chemical modification to mitigate immunogenicity
- Long-term stability

## 5 Nucleotides building blocks

- Develop novel building blocks
- Develop Galnac molecule with in-house IP
- Scalable building blocks manufacturing technology

## 6 Highly expandable platform

- Each individual component can be continuously upgraded
- Integrated manufacturing capabilities for building blocks, API and drug products






## 1 Payload platform

Multiple payload types for different cancer treatment mechanism of actions

- microtubule inhibitor
- Topoisomerase inhibitors
- Protein degrading agent
- DNA alkylating agent
- DNA repair inhibitors
- Immunoagonists
- Immunosuppressants
- hormone



## 2 Linker platform

Various linker design for stability, PK and other purpose beneficial for ADCs

- Hydroflex platform ensures hydrophilicity, stability and PK
- TMEC the TME payload released platform overcomes the problem of non-internalize targets
- Novel ESIM self-immolation platform enhances drug release efficiency.
- The HighDAR platform makes it possible to use low potent payloads in ADC

## 3 Conjugation platform

Including mainstream conjugation technology and proprietary site-specific conjugation technology with IP rights.

- Conventional lysine and cysteine conjugation platforms
- SmartQTag enzyme-mediated conjugation technology
- Glycan-engineered site-specific conjugation technology

## 4 New molecular entity

Multiple ADC drug molecules provide more clinical treatment options, and overcome the drug resistance of current existing therapies.

ADC Antibody-drug conjugate	ISAC Immune-stimulating antibody conjugate	DAC Degradable-antibody conjugate	dpAC Dual-payload antibody conjugate	CA-ADC Conditional-activated-ADC	Bs-ADC Bispecific-ADC	PDC Peptide-drug conjugate
Cytotoxin	Immune-stimulator	Protein degrader	Synthetic lethal	pH-activated mAb	Dual-epitope	Peptide



# Bispecific Antibody Platform

## Antibody-interferon fusion protein platform

### Structural advantages

- Synergistic binding effect when targeting the same cell
- Smaller molecular weight (smaller than that of conventional antibodies)

### Safer impurities

- The activity of interferon-containing impurities is far lower than that of conventional bispecific antibodies.
- No serious safety risk of interferon-containing impurities from the production process


### Stronger target selectivity

- Limited binding activity to receptors on TAA – cells, demonstrating a wider therapeutic window
- The optimizing of interferon mutation further improves target selectivity


### More stable product

- More efficient in CMC development
- Significantly reduces the interferon breakage during the production and in vivo, resulting in high yield and low risk

- ✓ High expandability : quickly forms new molecules
- ✓ Better safety profile : much safer than interferon
- ✓ More effective in tumor killing: much stronger than interferon
- ✓ remodels the tumor immune micro environment: enhances immune cell infiltration and MHC1 presentation
- ✓ Lower production cost : high efficiency, low toxicity, and simple process





## CD47-targeting bifunctional fusion protein platform



- ✓ Does not bind to TAA-/CD47+cells, including erythrocytes, platelets, etc.
- ✓ TAA-dependency enhances CD47 competitive binding
- ✓ High expandability: various types of tumor-targeting antibodies could be used as the left-arm
- ✓ Wider safety window
- ✓ Lower molecular weight, better suits solid tumors
- ✓ Simple production process
- ✓ Possession of intellectual property right

### Mechanism





Part 04

# Pipeline

# Candidates under Clinical Trial Stage

(26)

PhI

NBL-012 IL23-P19	NBL-015 CLDN18.2 mAb	NBL-020 TNFR2
NBL-028 CLDN6-CD137	SYS6002 Nectin-4 ADC	SYS6010 EGFR ADC
SYS6011	JMT203 GFRAL	Secukinumab
SYHA1801 BRD4	SYHA1803 Pan-FGFR	SYHA1805 FXRs
SYHA1807 LSD1	SYHA1811 BTK	SYHA1815 FGFR/RET
SYHX1903 CDK9	SYHX2001 PRMT5	SYHX2005 FGFR4
SYHX2009 NTRK/ROS1	SYH2038 SOS1	SYH2043 CDK2/4/6
SYH2045 PRMT5	SYH2051 ATM	SYH2053 PCSK9
SYHA1908		Cisplatin micelle

(15)

PhII (POC)

CLDN18.2 ADC	CM326 TSLP
ALMB0166 Cx43i mAb	ALMB0168 Cx43s mAb
JMT601 CD20/CD47	SYHX1901 JAK/SYK
Simmitinib TKI	SYHA1813 VEGFR/CSF1R
Amuxetine 5-HT/NE	SYHA1402 ARi
NBP Capsule (US PhII)	Paclitaxel cationic liposome
Albumin-bound Sirolimus	Octreotide long- acting injection
Alprostadi liposome	

(16)

PhIII / III pivotal trial

JMT101 EGFR mAb	CM310 IL4R
KN026 Her2 BsAb	TG103 Fc-GLP1
Pertuzumab	Ulsinumab
DP303C HER2 ADC	NBP Capsule (VaD)
Batoclimab	Semaglutide
JMT103 bone metastasis	Albumin-bound Docetaxel
Albumin-bound Paclitaxel II	Mitoxantrone hydrochloride liposome (NPC)
Clevipidine injectable emulsion	Daunorubicin cytarabine liposome

(7)

NDA

SYSA1802 PD-1
Omalizumab biosimilar
DBPR108 DDP4
Amphotericin B Liposome
Meloxicam nanocrystal injection
Irinotecan liposome (US)
Amphotericin B Liposome (US)

Biological Agents  
 Chemical Drugs  
 New formulations

# Pipeline - Biological Agents


Over 40 new biologic drugs under development: 2 filed BLA, 23 under clinical trial stage(9 under pivotal trial stage) and over 10 under pre-clinical stage

TA	Major Candidates	Target	Indication (s)	Pre-clinical	Phase I	Phase II	Ph II / III pivotal trial	NDA	
Oncology	JMT103	RANKL	GCTB, osteoporosis, bone metastasis	Marketeted(GCTB)					★ BLA
	SYSA1802 (SG001)	PD-1	Tumors						★ BLA
	JMT101	EGFR	Multiple solid tumors						
	DP303c	HER2 ADC	Breast cancer						
	Pertuzumab biosimilar	HER2	Breast cancer						
	KN026	HER2 BsAb	Gastric cancer, breast cancer						
	SYSA1801*	Claudin 18.2 ADC	Gastric cancer, pancreatic cancer						
	ALMB0168	CX43 agonist	Bone cancer, cancer bone metastasis						
	JMT601*	CD47/CD20	NHL& multiple hematologic tumors						
	SYS6002*	Nectin-4 ADC	Tumors						
	NBL-028	CLDN6-CD137	Advanced tumors						
	NBL-020*	TNFR2	Advanced solid tumor						
	SYS6010*	EGFR ADC	Tumors						
	SYS6011	Undisclosed	Solid tumors						
	NBL-015*	Claudin 18.2 mAb	Advanced solid tumors						
	JMT203	GFRAL	Cancer cachexia						

\*The product was developed in both China and the U.S.



# Pipeline - Biological Agents



\*approval for US & china


# Pipeline - Chemical Drugs

Over 40 small molecule new drugs under development: 1 filed NDA, 23 under clinical trial stage (2 under Phase III / pivotal trial stage) and about 20 under pre-clinical stage

TA	Major Candidates	Target	Indication (s)	Pre-clinical	Phase I	Phase II	Ph II / III pivotal trial	NDA	
<b>Digestion &amp; metabolism</b>	DBPR108	DPP-4	Diabetes	[Progress bar]					★ NDA
	Semaglutide	GLP-1	Type2 diabetes	[Progress bar]					
	SYH2053	PCSK9	FH, Mixed hyperlipidemia	[Progress bar]					
	SYHA1805	FXR Agonist	NASH(MASH)	[Progress bar]					
<b>Nervous system</b>	NBP soft capsule*		VaD, Ischemic stroke(US)	[Progress bar]					
	SYHA1402	ARI	Diabetic neuropathy	[Progress bar]					
	Amuxetine hydrochloride enteric tablets	5-HT, SNDRI	Anti-depressant	[Progress bar]					
<b>Immune</b>	SYHX1901	Syk-Jak	RA, SLE, COVID-19	[Progress bar]					
	Simmitinib	FGFR, KDR	Gastric cancer, cholangiocarcinoma, SQCC	[Progress bar]					
	SYHA1813	VEGFR/CSF1R	Relapsed or advanced solid tumour	[Progress bar]					
<b>Oncology</b>	SYHX2005	FGFR4	Advanced solid tumor	[Progress bar]					
	SYH2043	CDK2/4/6	Breast cancer	[Progress bar]					
	SYH2045	PRMT5	Advanced malignant tumors	[Progress bar]					
	SYH2051	ATM	Solid tumor	[Progress bar]					

# Pipeline - New formulations

Over 30 new preparations under development: 2 applied marketing approval, 11 under clinical trial (5 under pivotal trial stage ), and over 20 under pre-clinical stage



\*The product was developed in both China and the U.S.

# Pipeline Products Launch Plan

> 50 New Drugs /Indications approved in coming 5 years (Expected )

- Vaccine
- Biological Agents
- Chemical Drugs
- New formation
- Non-Chinese region







# Common Generics Launch Plan

**17 applications have been filed for marketing approvals, expecting to receive approval in 2024-2025;  
Over 20 candidates under pharmaceutical research, expecting to receive approval in 2026-2027**

No.	Product	Therapeutic Area	Expected to be launched
1	Dapagliflozin tablets	Digestion & Metabolism	2024
2	Rabeprazole sodium enteric-coated tablets (10mg)	Digestion & Metabolism	2024
3	Olaparib tablets	Oncology	2024
4	Palbociclib tablets (125mg)	Oncology	2024
5	Lenalidomide capsules (5mg, 10mg)	Oncology	2024
6	Peramivir injection (150mg/15ml)	Anti-infective	2024
7	Aprepitant injection	Others	2024
8	Dexrazoxane for injection	Others	2024
9	Roxadustat capsules	Others	2024
10	Peramivir Injection (300mg/60ml)	Anti-infective	2025
11	Regorafenib tablets	Oncology	2025
12	Ilaprazole enteric-coated tablets	Digestion & Metabolism	2025
13	Terezolamide phosphate tablets	Anti-infective	2025
14	Oseltamivir phosphate for oral suspension	Anti-infective	2025
15	Mesalazine enteric-coated tablets	Autoimmunity	2025
16	Vonorazone fumarate tablets	Digestion & Metabolism	2025
17	Adenosine cobalamin capsules	Others	2025




# IND Approvals Obtained as now

IND approval for the 1st indication (22)	
SYH2045 (Solid tumors)	Meloxicam nanocrystal injection (moderate-to-severe pain for adults)
Clevidipine injectable emulsion (Hypertension)	Octreotide long-acting injection (acromegaly)
NBL-020 (Advanced solid tumors)	SYS6010 (advanced solid tumors)
SYH2051 (Solid tumors)	JMT203 (tumor cachexia)
Semaglutide injection (Type 2 diabetes)	NBL- 028 (Advanced tumors)
SYS6006.32 (Bivalent COVID-19 mRNA vaccine)	Secukinumab injection (Psoriasis)
SYS6011 (Solid tumors)	SYH2038 (Advanced solid tumor)
Dextromethorphan hydrobromide quinidine sulfate tablets (Pseudobulbar paralysis)	SYH2053 injection (Primary hypercholesterolemia or mixed dyslipidemia in adults)
Dexmedetomidine hydrochloride nasal spray (Sedation before invasive examination)	JMT106 injection (Solid tumor) (U.S.)
CPO301 (Advanced solid tumors) (U.S. & Canada)	NBL- 028 injection (U.S.), NBL- 020 injection (U.S.)



# IND Approvals Obtained as now

IND approval for additional indications (24)	
KN026 injection (in combination with docetaxel albumin for treatment of first-line HER2 positive recurrent and metastatic breast cancer)	Docetaxel for injection (albumin-binding), five indications were approved
JMT101 injection (in combination with docetaxel albumin for treatment of second-line squamous cell non-small cell lung cancer)	Enransubezumab injection (SG-001) (Combined chemotherapy for first-line cervical cancer)
Paclitaxel cationic liposome for injection (Advanced solid tumor - arterial infusion chemotherapy)	Simetinib (Combined with SG001 for solid tumor, combined with irinotecan liposomes for second-line and above esophageal cancer)
JMT101 injection (Combined with SG001 and irinotecan for colorectal cancer)	ALMB-0166 (Acute ischemic stroke)
Bartolizumab (Proliferative lupus nephritis)	CM326 (COPD) 、 CM310 (COPD)
JMT601 injection (Combined with different regimes for CD20-positive diffuse large B-cell lymphoma)	SYHX1901 tablets (Vitiligo, alopecia areata)
Octreotide Long-acting Injection (Gastrointestinal and Pancreatic Neuroendocrine Tumors)	SYSA1801 injection (Combined with SG001 and CAPOX for the first-line treatment of CLDN18.2-positive, HER2-negative, unresectable locally progressive or metastatic gastric or gastroesophageal junction adenocarcinoma)
Sirolimus for injection (albumin-binding) in combination with endocrine therapy for second-line and above HR-positive HER2-negative advanced breast cancer	Cisplatin micelles (Combined with paclitaxel for advanced solid tumors)



Part 05  
**BD&ESG**



# BD Strategic Layout and Path of Advancement

## Focusing on strategic domains, deepening BD strategies, and establishing an international BD ecosystem

**BD Product Positioning:** Aligning closely with clinical needs, emphasizing clinical benefits, grasping international cutting-edge technology and product trends, strengthening areas of group advantage, focusing on key clinical stage products in the mid to late phases.

**BD Technology Platforms:** Actively exploring collaboration and development of early-stage products with AI pharmaceuticals, nucleic acid drug antigen screening platforms, gene therapy technologies, novel vaccine development platforms, and intratumoral injection technology platform.

**Internationalization of BD:** Pursuing a dual strategy of both licensing in and out, expanding international projects with leading multinational pharmaceutical companies and Belt and Road initiatives, reinforcing strategic relationships with fund institutions having overseas resources, and advancing the connection and collaboration of global projects.

**BD Ecosystem Construction :** BD Ecosystem Construction: Leveraging the advantages of group clinical development, product registration, and commercialization resources, adopting a Pharma+Biotech win-win model, engaging in extensive and in-depth collaboration with Biotech companies or research institutions that possess innovative advantages, including practical and feasible merger and acquisition models, to continue supporting the group's external innovation.

## BD Work Completion Status for 2023

### ■ License-out:

- Granted Corbus Pharmaceuticals the development and commercialization rights for SYS6002 (Nectin-4ADC, Phase 1) in the United States, European Union countries, the United Kingdom, Canada, Australia, Iceland, Liechtenstein, Norway, and Switzerland.

### ■ License-in:

- Obtained Pfizer's exclusive authorization to locally market the oral antiviral COVID-19 treatment medication, Namatavir Tablets/Litoconavir Tablets, in China



# BD Key Therapeutic Area Strategy for 2023

## Reinforce Leading Position in Established Areas


- Comprehensive Management of Stroke Disease, with a Focus on the Strategic Positioning and Collaboration of Innovative Drug Projects in Vascular Recanalization, Neuroprotection, and Anti-Inflammation that Synergize with the Company's Existing Resources
- Attention to Late-stage Clinical or Newly Approved Drugs in the Alzheimer's Disease (AD) Field, as well as Emerging Novel Targeted Therapeutics.

### Neurology Field



- Strengthen differentiation in hematologic malignancies, lung cancer, and breast cancer, focusing on targeted therapies, new immunotherapies, and combination treatments.
- Explore innovative drugs in areas such as digestive tract tumors, gynecological tumors, and urological tumors.
- .

### Oncology Field



- Focus on challenging areas like refractory hypertension, hyperlipidemia, and heart failure. Pay attention to long-acting, oral diabetes/weight reduction innovative products.
- Address thyroid diseases and innovative treatments related to gout.

### Cardiovascular & Endocrinology Field



- Emphasize areas like idiopathic pulmonary fibrosis (IPF), COPD/asthma, and cough, exploring innovative targets, drug-device combinations, and drug delivery systems.
- Focus on high-end antibiotics effective against clinically resistant bacteria.
- Address conditions such as atopic dermatitis, systemic lupus erythematosus, and inflammatory bowel disease (IBD).

### Respiratory, Autoimmune & Anti-Infective Field



## Explore Novel Therapeutic Areas and Technology Platforms

- Address primary and secondary kidney diseases like IgA nephropathy and diabetic nephropathy.
- Focus on complications of kidney diseases like renal anemia, hyperphosphatemic kidney disease, hypertension, and kidney-related itching.

### Nephrology Field



- Concentrate on well-established companies with mature late-stage ophthalmology pipelines.
- Focus on products for treating retinal diseases like AMD using new targets, long-acting formulations, nanomedicines, and gene therapies, with a special focus on geographic atrophy indications.

### Ophthalmology Field



- Focus on therapeutic nuclear medicine, breaking through new targets, new indications, and new isotopes while avoiding homogenization.
- Focus on larger market opportunities in solid tumor such as prostate cancer, lung cancer, breast cancer, gastrointestinal tumors under new nuclides and new target combination

### Nuclear Medicine Field



- Expand into major population-based psychiatric disorders like depression and schizophrenia, focusing on the layout and collaboration of novel targeted drugs with improved efficacy, safety, and compliance.
- Emphasize fast-acting nasal spray formulations.

### Psychiatry Field



- Chronic Pain: Focus on innovative drug projects that provide better pain relief, higher safety, and non-addictive properties.
- Acute Pain: Concentrate on innovative projects that extend postoperative pain relief duration while maintaining higher safety.

### Pain Management Field




- Focus on unmet clinical needs in orthopedics, from completely innovative products to products that improve patient accessibility, and tap opportunities in orthopedics
- Focus on spine surgery-related drugs, osteoporosis iterations

### Orthopedics Field



# Aim to Become an ESG Leader in Pharmaceutical Industry



- Awarded “China’s Top Healthiest Workplace” by Mercer, “AAA Enterprise with Harmonious Labour Relations in Hebei Province” and “National Advanced Enterprise in Employment”

- Achieved “Five Zeros and One Low”\*
- The major shareholder of the Group granted 220M conditional shares to over 300 employees in 2022

- Improving board diversity continuously
- Structural reduction of carbon emissions - the ratio of innovative drugs /formulations increasing and the ratio of APIs decreasing
- Invested RMB763m in smart manufacturing, equipment upgrade and modification
- Plan to invest more than RMB100m per year to support the upgrade of environment protection center
- Ouyi, NBP, CSPC Innovation, Factory in Taizhou (our subsidiaries) are recognized as “Green Factories” by the MIIT

- Adhere to the procurement principle of “fair, impartial, green and transparent”
- Online bidding and procurement; supplier integrity commitment; *Blacklist Management System for Dishonesty*

- Employee assistance: In 2023, a total of 81 employees and their families were helped
- CSPC Education Assistant Fund- helped 2024 college students in 2023
- Cancer and critical illness patients assisting program- assisted 42 patients in 2023
- Medical care program for poor children- helped 42 children with hemopathy in 2023
- Patient assisting program: the number of aid recipients reached 59300 in 2023.



## Environmental Protection Plan 2025

- ✓ Reduce greenhouse gas emissions per unit of revenue by 50.66%
- ✓ Reduce the emission of non-hazardous waste (general solid waste) per unit of revenue by 70.7%
- ✓ Reduce the discharge of hazardous waste per unit of revenue by 26%
- ✓ Reduce the comprehensive energy consumption by 56.57%
- ✓ Reduce the water consumption per unit of revenue by 35.52%




\*Five Zeros and One Low- zero cases of death, serious injuries, multiple injuries, occupational disease and poisoning incident as well as low incident rate of minor injuries

\*The emission reduction target is based on the emission in 2017



WeChat of CSPC IR Team:



**Thanks!**